Showing 2921-2930 of 5621 results for "".
- Stuart Therapeutics Publishes New Study Demonstrating Potential of Collagen Mimetic Peptides in Treating Ophthalmic Diseasehttps://modernod.com/news/stuart-therapeutics-publishes-new-study-demonstrating-potential-of-collagen-mimetic-peptides-in-treating-ophthalmic-disease/2482887/Stuart Therapeutics announced the publication of a preclinical study in Pharmaceuticals highlighting the potential of collagen mimetic peptides (CMPs) in restor
- Ocumetics Initiates First-In-Human Study of Accommodating Intraocular Lenshttps://modernod.com/news/ocumetics-initiates-first-in-human-study-of-accommodating-intraocular-lens/2482866/Ocumetics Technology has initiated the first-in-human (FIH) clinical studies for its accommodating intraocular lens, known as the Ocumetics Lens. Designed to mimic the natural focusing ability of the youthful hu
- Ocular Therapeutix To Close Enrollment this Week for SOL-R Trial Evaluating Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-to-close-enrollment-this-week-for-sol-r-trial-evaluating-axpaxli-in-wet-amd/2482822/Ocular Therapeutix announced that enrollment in the SOL-R registrational trial of its product candidate Axpaxli in wet age-related macular degeneration (AMD) will close this week. “Completing enrollment in SOL-R—the largest retinal TKI trial to date—one year
- The Alliance for Healthcare from the Eye Launches to Transform Disease Detectionhttps://modernod.com/news/the-alliance-for-healthcare-from-the-eye-launches-to-transform-disease-detection/2482801/A coalition of healthcare leaders announced the launch of the 'Alliance for Healthcare from the Eye (AHE)' at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City. AHE is a cross-sector initiative
- Aldeyra Plans to Resubmit NDA for DED Candidate Reproxalap After Dry Eye Chamber Trial Resultshttps://modernod.com/news/aldeyra-plans-to-resubmit-nda-for-ded-candidate-reproxilap-after-dry-eye-chamber-trial-results/2482788/Aldeyra Therapeutics announced it has achieved the primary endpoint in a phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial of its investigational drug candidate reproxalap.
- Iantrek Hits 2,000 Procedures for New Bio-Interventional Technology - AlloFlo Uveohttps://modernod.com/news/iantrek-hits-2000-procedures-for-new-bio-interventional-technology-alloflo-uveo/2482785/Iantrek announced it has surpassed 2,000 AlloFlo Uveo procedures in the US. The key milestone comes ahead of its full commercial launch planned for this fall during the American Academy of Ophthalmology 2025 meeting. Recent momentum has been fueled by the publication of 2-year
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication
- Lighthouse Guild Appoints Thomas Panek as New President and CEOhttps://modernod.com/news/lighthouse-guild-appoints-thomas-panek-as-new-president-and-ceo/2482706/Lighthouse Guild announced this morning that Thomas Panek has been appointed as President and CEO, effective April 2025. He succeeds Dr. Calvin W. Roberts, who has served in this role for the past 5 years. Mr. Panek has significant leadership experience with a deep commitment to a
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLs in the European Unionhttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols-in-the-european-union/2482610/Bausch + Lomb announced the commercial launch of the enVista Aspire monofocal and toric IOLs in the European Union after receiving a CE Mark late last year. According to B+L, enVista Aspire combines 'intermediate optimized' optics, which are designed for a broader dept
- Alkeus Announces Interim TEASE-3 Study Results Evaluating Gildeuretinol in Early-Stage Stargardt Patientshttps://modernod.com/news/alkeus-announces-new-interim-tease-3-study-results-showing-gildeuretinol-prevented-disease-progression-in-early-stage-stargardt-patients/2482608/Alkeus Pharmaceuticals announced positive interim data from its TEASE-3 study demonstrating that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years. “Thes